title: Etoposide in recurrent childhood Langerhans' cell histiocytosis: an Italian cooperative study.
abstract: Eighteen evaluable children with recurrent Langerhans' cell histiocytosis (LCH) which was resistant to standard therapy, were treated with etoposide (VP 16-213), 200 mg/m2/day for 3 days every 3 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses were demonstrated in 15 patients (83.3%). Only one of the 12 children achieving a complete remission has relapsed. No dose-limiting major toxicities were registered. Although etoposide might be an effective treatment in recurrent LCH which needs a chemotherapeutic approach, it is emphasized that this drug must be used carefully.
authors.affiliation: Second Department of Pediatrics, University of Bari, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Ceci
authors.forename: M
authors.initials: M
authors.lastname: de Terlizzi
authors.forename: R
authors.initials: R
authors.lastname: Colella
authors.forename: D
authors.initials: D
authors.lastname: Balducci
authors.forename: M G
authors.initials: MG
authors.lastname: Toma
authors.forename: M G
authors.initials: MG
authors.lastname: Zurlo
authors.forename: P
authors.initials: P
authors.lastname: Macchia
authors.forename: A
authors.initials: A
authors.lastname: Mancini
authors.forename: P
authors.initials: P
authors.lastname: Indolfi
authors.forename: M
authors.initials: M
authors.lastname: Locurto
mesh_terms: D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D054747:Histiocytic Sarcoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007223:Infant; D007801:Langerhans Cells / Q000473:pathology*; D008297:Male; D012008:Recurrence
chemical_list: D005047:Etoposide